Literature DB >> 1633070

Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man.

M A Touchette1, P H Chandrasekar, M A Milad, D J Edwards.   

Abstract

Nine healthy male subjects received oral fluconazole 400 mg daily, ketoconazole 200 mg twice daily or no treatment for 6 days according to a randomized, cross-over design. A single 250 mg oral dose of phenytoin suspension was administered on day 5 and serum phenytoin concentrations were measured over the following 48 h. Serum testosterone concentrations were measured for 10 h after each dose of phenytoin. Ketoconazole had no significant effect on phenytoin concentrations while the mean AUC(0,48) for phenytoin was significantly higher with fluconazole (195.2 +/- 47.8 micrograms ml-1 h) than control (146.3 +/- 49.6 micrograms ml-1 h). At 48 h, the serum phenytoin concentration averaged 1.72 micrograms ml-1 under control conditions and 3.99 micrograms ml-1 with fluconazole (132% increase). AUC(0,10) for testosterone was 42% lower than control after ketoconazole administration (P less than 0.05) but increased by 33% from 55.6 +/- 9.4 ng ml-1 h (control) to 73.8 +/- 12.6 ng ml-1 h with fluconazole. AUC(0,10) values for the testosterone precursors androstenedione and 17 alpha-hydroxyprogesterone were significantly higher in the fluconazole treatment phase as were concentrations of luteinizing hormone. The mechanism and clinical significance of the increase in testosterone concentration caused by fluconazole remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1633070      PMCID: PMC1381379          DOI: 10.1111/j.1365-2125.1992.tb04111.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Comparison of two azole antifungal drugs, ketoconazole, and fluconazole, as modifiers of rat hepatic monooxygenase activity.

Authors:  J B Houston; M J Humphrey; D E Matthew; M H Tarbit
Journal:  Biochem Pharmacol       Date:  1988-02-01       Impact factor: 5.858

2.  Effect of fluconazole on the disposition of phenytoin.

Authors:  R A Blum; J H Wilton; D M Hilligoss; M J Gardner; E B Henry; N J Harrison; J J Schentag
Journal:  Clin Pharmacol Ther       Date:  1991-04       Impact factor: 6.875

3.  Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.

Authors:  C J Doecke; M E Veronese; S M Pond; J O Miners; D J Birkett; L N Sansom; M E McManus
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

4.  Fluconazole and testosterone: in vivo and in vitro studies.

Authors:  D P Hanger; S Jevons; J T Shaw
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

5.  Ketoconazole blocks testosterone synthesis.

Authors:  A Pont; P L Williams; S Azhar; R E Reitz; C Bochra; E R Smith; D A Stevens
Journal:  Arch Intern Med       Date:  1982-11

6.  Drug interactions with fluconazole.

Authors:  J D Lazar; K D Wilner
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

7.  Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes.

Authors:  D J Back; J F Tjia
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

8.  Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.

Authors:  S K Yamashita; E A Ludwig; E Middleton; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1991-05       Impact factor: 6.875

Review 9.  Inhibitors of steroid 5 alpha-reductase in benign prostatic hyperplasia, male pattern baldness and acne.

Authors:  B W Metcalf; M A Levy; D A Holt
Journal:  Trends Pharmacol Sci       Date:  1989-12       Impact factor: 14.819

10.  Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients.

Authors:  M R First; T J Schroeder; J W Alexander; G W Stephens; P Weiskittel; S A Myre; A J Pesce
Journal:  Transplantation       Date:  1991-02       Impact factor: 4.939

View more
  13 in total

1.  The use of urine to clarify the genotype of a patient with toxic phenytoin concentrations who had undergone peripheral blood stem cell transplantation.

Authors:  Noritaka Ariyoshi; Katsuhiro Sho-no; Miki Nishimura; Michihiro Ito; Hiroyoshi Nakamura; Takayoshi Asai; Yasushi Saitoh; Takashi Ishizaki; Mitsukazu Kitada
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

2.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 3.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 4.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

Review 5.  Systemic antifungal agents. Drug interactions of clinical significance.

Authors:  E Albengres; H Le Louët; J P Tillement
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

Review 6.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of fluconazole.

Authors:  D Debruyne; J P Ryckelynck
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

Review 8.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

9.  Effect of fluconazole on theophylline disposition in humans.

Authors:  H Konishi; K Morita; A Yamaji
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

10.  Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration.

Authors:  Lynn Purkins; Nolan Wood; Parviz Ghahramani; Edward R Love; Malcolm D Eve; Anitra Fielding
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.